老化的大脑和晚期发病的耐药性
1Institute of Pharmacology, Toxicology & Pharmacy, Ludwig-Maximilians-Universität (LMU), Munich, Germany.
Seizure
|October 15, 2024
概括
老年人中耐药性是一种挑战,老龄化对药物反应和大脑网络的影响往往会加剧. 需要更多的研究来了解和有效治疗这种情况.
科学领域:
- 神经学 神经学
- 老年学是指老年学的学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚发性 (LOE) 通常对药物反应良好,但大量老年患者患有耐药性 (DRE).
- 在这个人群中,DRE显著影响生活质量,并增加了与有关的受伤风险.
- 挑战包括老年患者常见的多病症和多药疗法.
研究的目的:
- 研究晚发性中药物耐药性背后的机制.
- 探索衰老对抗发作药物的药理动力学和药理动力学的影响.
- 突出需要加强对老年人DRE预测算法的研究和开发.
主要方法:
- 对有关衰老,和抗药性现有文献的综述.
- 对影响老年人ASM疗效和毒性因素的分析.
- 讨论了解LOE中的DRE机制的知识差距.
主要成果:
- 细胞,分子和代谢网络中与衰老相关的变化会影响的严重程度和神经功能.
- 虽然药理动力学变化可能会增加对较低剂量的ASM敏感性,但改变的药理动力学和网络刺激性有助于耐药性.
- 在了解DRE的具体机制和老年人群中影响因素方面存在重大差距.
结论:
- 晚发性的耐药性是复杂的,受老化过程的影响,影响大脑和药物代谢.
- 进一步的实验和临床研究对于阐明DRE机制和为老年患者开发个性化治疗策略至关重要.
- 需要考虑患者异质性的多变量预测算法,以优化晚发性中DRE的管理.
相关概念视频
Arteries of the Lower Limbs
178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Glutamate Antagonists
287
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
287
Antiepileptic Drugs: Potassium Channel Activators
148
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
148
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
263
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
263
Antiepileptic Drugs: GABAergic Pathway Potentiators
338
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
338
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166


